BRIEF-Cansino Biologics Says Ad5-nCoV Granted Emergency Use Authorization In Pakistan

Cansino Biologics Inc:

* AD5-NCOV GRANTED EMERGENCY USE AUTHORIZATION BY DRUG REGULATORY AUTHORITY OF PAKISTAN

* INTERIM RESULTS FOR PHASE III CLINICAL TRIAL OF COVID-19 VACCINE AD5-NCOV GRANTED EMERGENCY USE AUTHORIZATION IN PAKISTAN Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0216/2021021600025.pdf Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)